Theravance Biopharma, Inc.

NASDAQ:TBPH

Biotechnology

Healthcare
$17.03 -0.42%

-$0.07 today

Market cap
$882.64M
Beta
0.18
P/E (TTM)
7.4
EPS (TTM)
$2.23
52W Low $10.44High $21.03

Volume 10.02M

Average 0.43M

TBPH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Theravance Biopharma, Inc.NASDAQ: TBPH

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 91.9%

Gross margin was 91.9% in Q1 FY2026, up 66.3 pp from a year earlier. On a trailing-twelve-month basis it was 80.4%, up 41.9 pp year over year. Over 3 fiscal years it widened by 118.3 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
91.9%-4.8 pp QoQ
Last fiscal yearDec 2025
94.9%+53.3 pp YoY
LTMMar 2026
80.4%+41.9 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+66.3 pp——
1 year+53.3 pp——
3 years+118.3 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
94.9%
Year-over-year change
+53.3pp

Gross Margin vs competitors

How TBPH compares with its peers on the latest reported figures

  • TBPH's LTM Mar 2026 gross margin of 80.4% is the 5th highest of the 6 companies compared; the peer median is 91.2%.
  • Its year-over-year change of +41.9 pp is the 2nd highest of 5, against a peer median of -7.4 pp.
  • Over three fiscal years its change of +118.3 pp compares with a peer median of +9.4 pp.
TBPH Competitors Peer median
Gross Margin for TBPH and competitors
Company Period LTM level YoY 3-year change
VIRVir Biotechnology, Inc.LTM Mar 2026275.2% +2604.6 pp+21.4 pp
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 202695.3% -3.4 pp—
LENZLENZ Therapeutics, Inc.LTM Mar 202691.2% —-3.7 pp
GERNGeron CorporationLTM Mar 202686.6% -11.3 pp-2.6 pp
TBPHTheravance Biopharma, Inc.LTM Mar 202680.4% +41.9 pp+118.3 pp
VALNValneva SELTM Mar 202629.5% -17.1 pp+28.5 pp
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
TYRATyra Biosciences, Inc.FY2025— ——
REPLReplimune Group, Inc.FY2025— ——
Peer median (excluding TBPH) 91.2%-7.4 pp+9.4 pp

Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.31M51.35M57.42M64.38M107.46M
Cost of Revenue193.66M63.39M40.62M37.64M5.52M
Gross Profit(138.35M)(12.05M)16.8M26.74M101.95M
Gross Margin-250.1%-23.5%29.3%41.5%94.9%
Research & Development201.55M70.07M46.34M38.05M37.41M
Selling, General & Admin99.3M67.07M70.45M69.17M73.65M
Operating Expenses119.44M79.91M72.84M73.69M115.2M
Depreciation & Amortization4.81M3.04M2M3.62M5.52M
EBITDA(232.83M)(76.08M)(51.65M)(38.45M)137.22M
EBITDA Margin-420.9%-148.2%-89.9%-59.7%127.7%
Operating Income(257.78M)(91.96M)(56.04M)(46.95M)(13.25M)
Operating Margin-466.1%-179.1%-97.6%-72.9%-12.3%
Interest Income1.11M8.55M9.12M4.88M0
Interest Expense8.55M6.37M2.35M2.55M2.46M
Other Income / Expenses(7.44M)(858K)6.77M2.34M142.49M
Income Before Tax(265.22M)(92.82M)(49.27M)(44.61M)129.25M
Pre-Tax Margin-479.5%-180.8%-85.8%-69.3%120.3%
Income Tax Expense(151K)9K5.92M11.8M23.35M
Net Income(199.43M)872.13M(55.19M)(56.42M)105.9M
Net Margin-360.6%1698.5%-96.1%-87.6%98.5%
EPS (Basic)(2.87)(1.26)(1.00)(1.15)2.10
EPS (Diluted)(2.87)(1.26)(1.00)(1.15)2.06
Weighted Avg Shares69.46M73.59M55.3M48.85M50.32M
Weighted Avg Shares (Diluted)69.46M73.59M55.3M48.85M51.51M

Theravance Biopharma, Inc.

NASDAQ:TBPH

Intrinsic Alpha fair value

Locked

Current Price

$17.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.